SENS Shares Surge After First Commercial Patients Use AID-Integrated Continuous Glucose Monitor System

• Broad availability of the twiist and Eversense 365 integrated product is expected by March 2026, as per the company. 
• Combining twiist with Senseonics’s Eversense 365 marks the first time when a one-year CGM system has been integrated with an AID, the company said.
• The commercial launch of the integrated products provides people with type 1 diabetes a new level of flexibility and personalization in their diabetes management.

Shares of Senseonics Holdings, Inc. (SENS) closed over 8% higher on Thursday after the company announced the first commercial usage of its year-long implantable Eversense 365 Continuous Glucose Monitor (CGM) with Sequel MedTech’s Automated Insulin Delivery (AID) system.

Senseonics said that alongside Sequel, it has launched the integration of the products with the first patients having received a Sequel twiist AID system paired with the Eversense 365 CGM.

Broad availability of the twiist and Eversense 365 integrated product is expected by March 2026, as per the company.

The company’s shares were up 0.14% in after-market hours at the time of writing.

World’s First AID Integration

Combining twiist with Senseonics’s Eversense 365 marks the first time when a one-year CGM system has been integrated with an AID, representing a major milestone in long-term diabetes management by reducing the need for regular sensor changes and re-pairing, while maintaining exceptional accuracy, the company said.

“Patients and providers want reliable, long-term automated glucose readings and we’ve taken a major step forward in simplifying and personalizing diabetes management by integrating Eversense 365’s One Year CGM system with the twiist AID system for patients that require insulin,” Goodnow said.

Meanwhile, Alan Lotvin, CEO of Sequel MedTech said that diabetes management is deeply personal, and no single approach works for everyone. “Our focus on personalization means Sequel is committed to creating choice for people living with diabetes; integration with the Eversense CGM is an important step in this journey, enabling more people to experience the precision and confidence that twiist AID system brings to diabetes management,” he added.

How Did Stocktwits Users React?

On Stocktwits, retail sentiment around SENS stock stayed in the ‘bullish’ territory over the past day amid ‘high’ message volumes.

Shares of SENS have lost over 17% of their value in the past year.

For updates and corrections, email newsroom[at]stocktwits[dot]com.
 

Share

·

Add us on